Evidence map›Paper›PMID 39702697›Full record

ArticleCancer chemotherapy and pharmacology2024

Predictive factors for first dose reduction and interruption of lenvatinib after beginning of the standard dose in Japanese patients with thyroid cancer.

Kazuma Fujita, Mitsuji Nagahama, Akifumi Suzuki, Chie Masaki, Kiminori Sugino, Koichi Ito, Masatomo Miura

Abstract read
PubMed Publisher
In one paragraph

Article in Cancer chemotherapy and pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kazuma FujitaDepartment of Pharmacy, Akita University Hospital, Akita, Japan.
Mitsuji NagahamaDepartment of Surgery, Ito Hospital, Tokyo, Japan.
Akifumi SuzukiDepartment of Surgery, Ito Hospital, Tokyo, Japan.
Chie MasakiDepartment of Surgery, Ito Hospital, Tokyo, Japan.
Kiminori SuginoDepartment of Surgery, Ito Hospital, Tokyo, Japan.
Koichi ItoDepartment of Surgery, Ito Hospital, Tokyo, Japan.
Masatomo MiuraDepartment of Pharmacy, Akita University Hospital, Akita, Japan. m-miura@hos.akita-u.ac.jp.

Funding

Japan Society for the Promotion of Science 20K07150
6 · The paper itself

Abstract

purposeThe associations between first dose reduction or interruption by side effects and lenvatinib plasma trough concentration (C

methodsPlasma samples were collected each week for 1 month and at the first incidence of side effects leading to dose reduction or interruption after beginning administration of 24 mg lenvatinib.

resultsThe area under the receiver operating characteristic curve was 0.789 at a lenvatinib C

conclusionsOn day 8 after administration of 24 mg lenvatinib, lenvatinib dose may be adjusted based on the target C

Indexed as

Phenylurea CompoundsQuinolinesThyroid NeoplasmsAdultAgedAged, 80 and overAntineoplastic AgentsDose-Response Relationship, DrugEast Asian PeopleFemaleHumansJapanMaleMiddle AgedProtein Kinase InhibitorsAntineoplastic AgentslenvatinibPhenylurea CompoundsProtein Kinase InhibitorsQuinolinesAdverse eventsDose reductionLenvatinibPlasma concentration

Identifiers

PMID39702697

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.